From API Synthesis To Drug Product Shelf Life: Keeping The Program Integrated

Drug development programs often face significant friction when transitioning active pharmaceutical ingredients into finished drug products, particularly when managing controlled substances. Engaging multiple third-party laboratories for release testing and stability studies introduces administrative hurdles, such as controlled-drug transfer permitting, shipping logistics, and mandatory analytical method transfers. These external handoffs ultimately add unwanted expense, operational risk, and timeline delays.

Consolidating API synthesis, formulation, sterile fill-finish, and long-term ICH stability testing within a single integrated framework protects cumulative process knowledge. Maintaining continuity under one roof streamlines regulatory compliance, eliminates redundant method transfers, and accelerates the pathway to reliable shelf-life management.

Learn how vertical integration minimizes transfer complexity and keeps critical drug development programs moving forward efficiently.